- Q1 2024 scPharmaceuticals Inc Earnings Call TranscriptMay 14, 2024$4.5 (+3.45%)Earnings
- Q4 2023 scPharmaceuticals Inc Earnings Call TranscriptMar 13, 2024$5.44 (+1.49%)Earnings
- Q2 2023 scPharmaceuticals Inc Earnings Call TranscriptAug 10, 2023$7.75 (-1.27%)Earnings
- scPharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- scPharmaceuticals Inc Annual Shareholders Meeting TranscriptJun 06, 2023
- Q1 2023 scPharmaceuticals Inc Earnings Call TranscriptMay 10, 2023$11.36 (+0.80%)Earnings
- Q4 2022 scPharmaceuticals Inc Earnings Call TranscriptMar 22, 2023$6.92 (-0.14%)Earnings
- scPharmaceuticals Inc at Cowen Health Care Conference TranscriptMar 08, 2023
- scPharmaceuticals Inc at SVB Securities Global Biopharma Conference (Virtual) TranscriptFeb 16, 2023
- scPharmaceuticals Inc at Jefferies London Healthcare Conference TranscriptNov 16, 2022
- Q3 2022 scPharmaceuticals Inc Earnings Call TranscriptNov 09, 2022$5.38 (-4.44%)Earnings
scPharmaceuticals Inc at Jefferies London Healthcare Conference Transcript
Good afternoon, everybody. Why don't we get started. For those of you who don't know me, I'm Glen Santangelo on the new Spec Pharma Analyst at Jefferies. We recently launched on the space not too long ago.
And one of the companies we're very excited about is scPharmaceuticals, which we're happy that we have presenting here today. To my left is the President and CEO, John Tucker; and in the audience out there, we have John Morris, who heads clinical development and medical affairs, regulatory affairs, whatever. So, thank you for joining us, that's really awesome.
And it was this one of the stories we are really excited about. It's a company that recently got approval on an interesting drug device combination. And we don't think many investors are paying attention, which we think really presents a great opportunity for folks ahead, of what could be a pretty interesting launch in the first quarter of 2023.
So with that, why don't I turn it over to John. He has some slides to run through and maybe at the end, if we have a few minutes, I may
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)